Segall Bryant & Hamill LLC Decreases Stock Position in Haemonetics Corporation $HAE

Segall Bryant & Hamill LLC lessened its stake in shares of Haemonetics Corporation (NYSE:HAE) by 9.6% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 19,346 shares of the medical instruments supplier’s stock after selling 2,064 shares during the period. Segall Bryant & Hamill LLC’s holdings in Haemonetics were worth $1,443,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in HAE. Dynamic Technology Lab Private Ltd purchased a new stake in Haemonetics during the first quarter valued at $468,000. AQR Capital Management LLC raised its position in shares of Haemonetics by 591.6% during the 1st quarter. AQR Capital Management LLC now owns 174,565 shares of the medical instruments supplier’s stock valued at $10,931,000 after buying an additional 149,325 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in shares of Haemonetics by 7.5% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 12,907 shares of the medical instruments supplier’s stock valued at $963,000 after acquiring an additional 898 shares during the last quarter. Royal Bank of Canada lifted its holdings in shares of Haemonetics by 2.3% in the 1st quarter. Royal Bank of Canada now owns 1,075,604 shares of the medical instruments supplier’s stock valued at $68,355,000 after acquiring an additional 24,650 shares during the last quarter. Finally, Invenomic Capital Management LP purchased a new position in Haemonetics in the first quarter worth about $6,783,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics Trading Up 1.2%

NYSE HAE opened at $80.56 on Wednesday. The stock has a market cap of $3.77 billion, a PE ratio of 24.64, a PEG ratio of 0.91 and a beta of 0.43. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $89.69. The company’s 50-day moving average price is $56.75 and its 200-day moving average price is $63.07. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, beating analysts’ consensus estimates of $1.12 by $0.15. The company had revenue of $327.32 million during the quarter, compared to analyst estimates of $311.61 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The firm’s revenue for the quarter was down 5.3% on a year-over-year basis. During the same quarter last year, the business posted $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Equities research analysts forecast that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on HAE. JPMorgan Chase & Co. restated a “neutral” rating and set a $62.00 price objective (down from $85.00) on shares of Haemonetics in a research report on Friday, August 8th. BTIG Research restated a “buy” rating and set a $88.00 price target on shares of Haemonetics in a report on Friday, November 21st. Barrington Research lifted their price objective on shares of Haemonetics from $86.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Raymond James Financial reissued an “outperform” rating and issued a $90.00 target price on shares of Haemonetics in a research note on Friday, November 14th. Finally, Needham & Company LLC raised their target price on shares of Haemonetics from $68.00 to $78.00 and gave the stock a “buy” rating in a report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.70.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.